...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
【24h】

Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.

机译:托珠单抗:阻断白介素6信号通路作为炎症性疾病的治疗策略。

获取原文
获取原文并翻译 | 示例
           

摘要

Interleukin (IL)-6 contributes to a myriad of physiologic and pathophysiologic processes. Among its many physiologic functions, IL-6 plays an active role in immunology, inflammatory responses, bone metabolism, arthritis and neoplasia. Overproduction of IL-6 has been implicated in the disease pathology of several inflammatory and autoimmune disorders, including rheumatoid arthritis, Castleman's disease, Crohn's disease and systemic-onset juvenile idiopathic arthritis. Interception of the IL-6 signaling pathway could thus represent a new treatment option for these diseases, given their refractory status to conventional therapy. Clinical studies with tocilizumab, a humanized monoclonal anti-IL-6 receptor antibody, have been undertaken to explore this option. Current short-term results indicate that tocilizumab dramatically improves disease activity and is well tolerated. Further long-term safety and efficacy studies are needed to confirm the therapeutic benefit of this antibody in inflammatory and autoimmune disorders.
机译:白介素(IL)-6促进了许多生理和病理生理过程。 IL-6在其许多生理功能中,在免疫学,炎症反应,骨代谢,关节炎和肿瘤形成中起着积极的作用。 IL-6的过量生产与几种炎性和自身免疫性疾病的疾病病理学有关,包括类风湿性关节炎,Castleman病,Crohn病和全身发作的幼年特发性关节炎。考虑到它们对常规疗法的难治性,因此拦截IL-6信号传导途径可能代表这些疾病的新治疗选择。为了研究这种选择,已经进行了人源化单克隆抗IL-6受体抗体托珠单抗的临床研究。当前的短期结果表明,tocilizumab可以显着改善疾病活动性,并且具有良好的耐受性。需要进一步的长期安全性和功效研究,以确认该抗体在炎症和自身免疫性疾病中的治疗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号